Title |
Inflamação e má resposta ao uso de eritropoetina na doença renal crônica
|
---|---|
Published in |
Jornal Brasileiro de Nefrologia, January 2015
|
DOI | 10.5935/0101-2800.20150039 |
Pubmed ID | |
Authors |
Wander Valadares de Oliveira, Adriano de Paula Sabino, Roberta Carvalho Figueiredo, Danyelle Romana Alves Rios |
Abstract |
The prevalence of kidney chronic disease (CKD) has increased in recent years and several risk factors have been associated with the onset and progression of CDK, such as obesity, hypertension and diabetes mellitus. In addition, anemia is one of the complications of CRD, mainly by iron and erythropoietin (EPO) deficiency and the management of this situation is with exogenous erythropoietin, but patients undergoing dialysis present chronic inflammatory process followed by EPO resistance and anemia, malnutrition, worse of atherosclerosis and increased mortality ratio. The aim of this study was to review the association of erythropoietin resistance and chronic inflammatory process in patients with chronic renal disease. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 110 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 19 | 17% |
Student > Bachelor | 17 | 15% |
Student > Postgraduate | 11 | 10% |
Researcher | 7 | 6% |
Professor | 6 | 5% |
Other | 23 | 21% |
Unknown | 27 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 39 | 35% |
Nursing and Health Professions | 10 | 9% |
Biochemistry, Genetics and Molecular Biology | 9 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
Agricultural and Biological Sciences | 5 | 5% |
Other | 11 | 10% |
Unknown | 30 | 27% |